Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDOV-Safe
- Development stage
- Phase 2
- Lead developer
- ViroMissile
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
IDOV-Safe is an intravenously deliverable oncolytic vaccinia virus developed as a novel cancer therapy. It is part of the ViroMissile platform and represents the first "safety switch" oncolytic virus designed to stop viral replication in healthy cells, thereby enhancing safety. The drug is engineered for improved survival in blood and resistance to clearance by natural killer (NK) and T-cells, which allows it to persist longer in circulation and target tumors more effectively. Preclinical data suggest that it is up to 10 times more effective against microsatellite stable colorectal cancer (MSS CRC) compared to previous approaches. Its mechanism includes direct tumor cell lysis via viral infection, enhancement of anti-tumor immunity, and inhibition of tumor angiogenesis[1][2][4][5][7].
- Brand names
- IDOV-Safe
- Other names
- IDOV-SafeIDOV-SAFETM
Beyond the preview
Go deeper on IDOV-Safe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDOV-Safe.